Resource impact template
NICE has produced a resource impact template that incorporates the following technology appraisal guidance for untreated EGFR mutation-positive advanced non-small-cell lung cancer:
- Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer (2026) NICE technology appraisal guidance 1122
- Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer (2025) NICE technology appraisal guidance 1060
This page was last updated: